Publications

Staff at Medicus Economics are proud of their contributions to scientific research. We have collaborated with academic and industry partners to publish our findings in a broad set of peer-reviewed journals. Following are selected publications from two disease areas, but we welcome the opportunity to share our work in other areas.

Oncology

[1] Garrison, Louis P., Si-Tien Wang, Hui Huang, Abbie Ba-Mancini, Hongliang Shi, Kristina Chen, Caroline Korves et al. “The cost-effectiveness of initial treatment of multiple myeloma in the US with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.” The Oncologist 18, no. 1 (2013): 27-36.
[2] Johnson, Scott J., Rachael A. Sorg, Rohit D. Borker, and Mei Sheng Duh. “Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer.” Clinical Ovarian and Other Gynecologic Cancer 5, no. 2 (2012): 67-77.
[3] Feinberg, Bruce A., Pradeep Jolly, Si-Tien Wang, Barry Fortner, Jeffrey Scott, James Gilmore, Maureen P. Neary, and Mei Sheng Duh. “Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.” Medical Oncology 29, no. 2 (2012): 786-794.
[4] Lafeuille, Marie-Hélène, Francis Vekeman, Si-Tien Wang, Matthew Kerrigan, Laura Menditto, and Mei Sheng Duh. “Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.” Leukemia & lymphoma 53, no. 6 (2012): 1146-1154.
[5] Epstein, Andrew J., and Scott J. Johnson. “Physician response to financial incentives when choosing drugs to treat breast cancer.” International journal of health care finance and economics 12, no. 4 (2012): 285-302.
[6] Carlson MDA, Herrin J, Back AL, Du Q, Epstein AJ, Barry CL, Cherlin EM, Morrison RS, Bradley EH. “The impact of hospice disenrollment on healthcare utilization and Medicare expenditures for patients with cancer.” Journal of Clinical Oncology 28 no. 28 (2010):4371-4375.
[7] Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. “Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review.” BJU international 105, no. 9 (2010): 1247-1254.
[8] Raptis, Anastasios, Mei Sheng Duh, Si‐Tien Wang, Ellison Dial, Ilias Fanourgiakis, Barry Fortner, Carole Paley, Nikita Mody‐Patel, Mitra Corral, and Jeffrey Scott. “Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.” Transfusion 50, no. 1 (2010): 190-199.
[9] Carlson, Melissa DA, Jeph Herrin, Qingling Du, Andrew J. Epstein, Emily Cherlin, R. Sean Morrison, and Elizabeth H. Bradley. “Hospice characteristics and the disenrollment of patients with cancer.” Health services research 44, no. 6 (2009): 2004-2021.
[10] Wu, Eric Q., Scott Johnson, Nicolas Beaulieu, Mateo Arana, Vamsi Bollu, Amy Guo, John Coombs, Weiwei Feng, and Jorge Cortes. “Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.” Current Medical Research & Opinion 26, no. 1 (2009): 61-69.
[11] Johnson, S. J., J. H. Bilenker, and A. J. Epstein. “The relative influence of clinical information, financial incentives, and other factors on physician’s choice of chemotherapy.” In ASCO Annual Meeting Proceedings, vol. 24, no. 18_suppl, p. 6002. 2006.

Cardiovascular Disease

[1] Epstein, Andrew J., Peter W. Groeneveld, Michael O. Harhay, Feifei Yang, and Daniel Polsky. “Impact of minimally invasive surgery on medical spending and employee absenteeism.” JAMA surgery 148, no. 7 (2013): 641-647.
[2] Lefebvre, Patrick, Craig I. Coleman, Brahim K. Bookhart, Si-Tien Wang, Samir H. Mody, Kevin N. Tran, Daisy Y. Zhuo, Lynn Huynh, and Edith A. Nutescu. “Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.” Journal of medical economics 17, no. 1 (2013): 52-64.
[3] Baker, Laurence C., Dendy S. Macaulay, Rachael A. Sorg, Melissa D. Diener, Scott J. Johnson, and Howard G. Birnbaum. “Effects of care management and telehealth: A longitudinal analysis using Medicare data.” Journal of the American Geriatrics Society 61, no. 9 (2013): 1560-1567.
[4] Epstein, Andrew J., Daniel Polsky, Feifei Yang, Lin Yang, and Peter W. Groeneveld. “Coronary revascularization trends in the United States, 2001-2008.” Jama 305, no. 17 (2011): 1769-1776.
[5] Baker, Laurence C., Scott J. Johnson, Dendy Macaulay, and Howard Birnbaum. “Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings.” Health Affairs 30, no. 9 (2011): 1689-1697.
[6] Groeneveld, Peter W., Andrew J. Epstein, Feifei Yang, Lin Yang, and Daniel Polsky. “Medicare’s policy on carotid stents limited use to hospitals meeting quality guidelines yet did not hurt disadvantaged.” Health Affairs 30, no. 2 (2011): 312-321.
[7] Groeneveld, Peter W., Daniel Polsky, Feifei Yang, Lin Yang, and Andrew J. Epstein. “The impact of new cardiovascular device technology on health care costs.” Archives of internal medicine 171, no. 14 (2011): 1289-1291.
[8] Epstein, Andrew J. “Effects of report cards on referral patterns to cardiac surgeons.” Journal of health economics 29, no. 5 (2010): 718-731.
[9] El Khoury H, E Merikle, C Roberts, M Wagner, Scott J. Johnson. “Cost-effectiveness of atorvastatin 10mg daily in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada.” Canadian Journal of Diabetes 33, no. 4 (2009):363-374.
[10] Ramsey, Scott D., Lauren D. Clarke, Craig S. Roberts, Sean D. Sullivan, Scott J. Johnson, and Larry Z. Liu. “An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.” Pharmacoeconomics 26, no. 4 (2008): 329-339.
[11] Ketcham, Jonathan D., and Andrew J. Epstein. “Medicaid preferred drug lists’ costs to physicians.” Medical care 46, no. 1 (2008): 9-16.
[12] Ross, Joseph S., Stephen S. Cha, Andrew J. Epstein, Yongfei Wang, Elizabeth H. Bradley, Jeph Herrin, Judith H. Lichtman, Sharon-Lise T. Normand, Frederick A. Masoudi, and Harlan M. Krumholz. “Quality of care for acute myocardial infarction at urban safety-net hospitals.” Health Affairs 26, no. 1 (2007): 238-248.
[13] Ross, Joseph S., Vivian Ho, Yongfei Wang, Stephen S. Cha, Andrew J. Epstein, Frederick A. Masoudi, Brahmajee K. Nallamothu, and Harlan M. Krumholz. “Certificate of need regulation and cardiac catheterization appropriateness after acute myocardial infarction.” Circulation 115, no. 8 (2007): 1012-1019.
[14] Ketcham, Jonathan D., and Andrew J. Epstein. “Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?.” PharmacoEconomics 24, no. 3 (2006): 27-40.
[15] Epstein, Andrew J. “Do cardiac surgery report cards reduce mortality? Assessing the evidence.” Medical Care Research and Review 63, no. 4 (2006): 403-426.
[16] Epstein, Andrew J., Saif S. Rathore, Harlan M. Krumholz, and Kevin GM Volpp. “Volume-based referral for cardiovascular procedures in the United States: a cross-sectional regression analysis.” BMC health services research 5, no. 1 (2005): 42.
[17] Rathore, Saif S., Andrew J. Epstein, Kevin GM Volpp, and Harlan M. Krumholz. “Hospital coronary artery bypass graft surgery volume and patient mortality, 1998–2000.” Annals of surgery 239, no. 1 (2004): 110.
[18] Epstein, Andrew J, Rathore SS, Volpp KGM, Krumholz HM. “Hospital percutaneous coronary intervention volume and patient mortality, 1998-2000: does the evidence support current procedure volume minimums?” Journal of American College of Cardiology 43, no.10 (2004): 1755-1762.